Mode
Text Size
Log in / Sign up

Meta-analysis finds no significant association between statin use and ALS survival outcomesDo statins help people with ALS live longer? A new analysis finds no clear link

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret no significant statin-ALS survival association cautiously given observational data limitations.

This meta-analysis examined the association between statin use and survival outcomes in patients with amyotrophic lateral sclerosis (ALS). The analysis included 3,739 participants from six studies, with 889 identified as statin users. The comparator was non-use of statins. The primary outcome was ALS survival.

The main finding showed no statistically significant association between statin use and ALS survival, with a log hazard ratio of -0.04 (95% confidence interval: -0.18 to 0.10). The analysis did not report absolute numbers for survival outcomes. The direction of any potential association was not reported.

Safety and tolerability data were not reported in the meta-analysis. Key limitations include heterogeneity in how statin exposure was defined across studies and likely residual confounding in the predominantly observational data. The evidence is described as limited, and the authors appropriately note this demonstrates association rather than causation.

For clinical practice, this meta-analysis provides no evidence to support or discourage statin use specifically for ALS survival outcomes. The findings should be interpreted with caution due to the observational nature of most included data and the methodological limitations noted. Statin prescribing decisions for ALS patients with comorbid conditions should continue to be based on standard cardiovascular risk assessments rather than anticipated effects on ALS progression.

When you're facing a progressive disease like ALS, you and your doctors look for anything that might help. One question that's come up is whether common cholesterol medications called statins could affect how long people with ALS live. A new analysis pooled data from six studies involving 3,739 people with ALS, 889 of whom were taking statins. The researchers looked specifically at survival outcomes.

What they found was clear: there was no statistically significant link between statin use and how long people with ALS lived. The numbers showed no meaningful difference in survival between those taking statins and those who weren't. The analysis didn't report on side effects or how well people tolerated the medications in this population.

It's important to understand what this analysis can and can't tell us. The evidence comes mostly from observational studies, which means researchers looked back at existing data rather than randomly assigning people to take statins or not. This type of study can't prove cause and effect—it can only show associations. The researchers also noted that different studies defined 'statin use' in different ways, and there were likely other factors they couldn't account for that might influence survival.

For now, this analysis provides the most comprehensive look yet at this question. It suggests that, based on the available evidence, statins don't appear to change survival outcomes for people with ALS. If you have ALS and are taking a statin for cholesterol management, this finding doesn't suggest you should stop—but it does indicate the medication likely isn't affecting your ALS progression.

What this means for you:
Statins don't appear to help people with ALS live longer, based on current evidence.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BackgroundAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with limited disease-modifying therapies and a poor overall prognosis. Statins, are commonly used for dyslipidemia, and have been proposed to exert cholesterol-independent actions including anti-inflammatory and potential neuroprotective effects. Prior studies, However, existing studies offer conflicting results regarding their impact on ALS survival. This systematic review and meta-analysis aimed to evaluate the association between statin use and survival outcomes in patients with ALS.MethodsA comprehensive literature search was conducted in PubMed, Scopus, and Web of Science from inception to September 2025. Studies were included if they reported survival outcomes for statin users vs. non-users among patients with ALS. Data on hazard ratios (HRs) were extracted and pooled using fixed- or random-effects models, depending on heterogeneity. Meta-regression and sensitivity analyses were performed to explore the influence of covariates such as age and gender.ResultsSix studies with 3,739 participants (889 statin users) met the inclusion criteria. The pooled analysis showed no statistical significant association between statin use and ALS survival [Log(HR) = −0.04; 95% CI: −0.18 to 0.10], with moderate heterogeneity (I2 = 24.85%).ConclusionThe pooled estimate in this meta-analysis did not show a statistically significant association between statin use and ALS survival; however, the evidence is limited by heterogeneity in statin exposure definitions and likely residual confounding in predominantly observational data. Further high-quality studies with large sample sizes are needed to determine whether specific subgroups may benefit/harm from statin therapy.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251160344; PROSPERO: CRD420251160344.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.